alabdy
07-19-2022, 04:08 AM
The coronavirus seems to be in retreat in the United States, with the number of cases across the country down about 25 percent compared with a couple of weeks ago. Hospitalizations and deaths are also falling.
So, what stage are we in with the pandemic? And how will developments such as a new antiviral treatment and the availability of booster shots affect things?
Guest: Apoorva Mandavilli (https://www.nytimes.com/by/apoorva-mandavilli?smid=pc-thedail), a science and global health reporter for The New York Times.
Sign up here (https://www.nytimes.com/newsletters/signup/NTTD?smid=pc-thedaily) to get The Daily in your inbox each morning. And for an exclusive look at how the biggest stories on our show come together, subscribe to our newsletter (https://www.nytimes.com/newsletters/the-daily?module=inline).
Background reading:
The authorization for booster shots applies to groups of people in the United States fully vaccinated with the Pfizer vaccine (https://www.nytimes.com/2021/09/24/us/politics/biden-booster-shots-moderna-johnson-johnson.html), but about 45 percent of the country’s fully inoculated people received Moderna or Johnson & Johnson doses.
Merck said it would seek authorization for molnupiravir, an antiviral pill that the company says is effective against Covid. Experts said such treatments could be a powerful tool against the virus (https://www.nytimes.com/2021/10/01/business/covid-antiviral-pill-merck.html).
Despite a fall in new cases, hospitalizations and deaths (https://www.nytimes.com/2021/10/06/us/covid-delta-us-surge-vaccines.html), public health officials said the pandemic remained a potent threat.
For more information on today’s episode, visit
nytimes.com/thedaily (http://nytimes.com/thedaily?smid=pc-thedaily)
. Transcripts of each episode will be made available by the next workday.
أكثر... (https://www.nytimes.com/the-daily)
So, what stage are we in with the pandemic? And how will developments such as a new antiviral treatment and the availability of booster shots affect things?
Guest: Apoorva Mandavilli (https://www.nytimes.com/by/apoorva-mandavilli?smid=pc-thedail), a science and global health reporter for The New York Times.
Sign up here (https://www.nytimes.com/newsletters/signup/NTTD?smid=pc-thedaily) to get The Daily in your inbox each morning. And for an exclusive look at how the biggest stories on our show come together, subscribe to our newsletter (https://www.nytimes.com/newsletters/the-daily?module=inline).
Background reading:
The authorization for booster shots applies to groups of people in the United States fully vaccinated with the Pfizer vaccine (https://www.nytimes.com/2021/09/24/us/politics/biden-booster-shots-moderna-johnson-johnson.html), but about 45 percent of the country’s fully inoculated people received Moderna or Johnson & Johnson doses.
Merck said it would seek authorization for molnupiravir, an antiviral pill that the company says is effective against Covid. Experts said such treatments could be a powerful tool against the virus (https://www.nytimes.com/2021/10/01/business/covid-antiviral-pill-merck.html).
Despite a fall in new cases, hospitalizations and deaths (https://www.nytimes.com/2021/10/06/us/covid-delta-us-surge-vaccines.html), public health officials said the pandemic remained a potent threat.
For more information on today’s episode, visit
nytimes.com/thedaily (http://nytimes.com/thedaily?smid=pc-thedaily)
. Transcripts of each episode will be made available by the next workday.
أكثر... (https://www.nytimes.com/the-daily)